5 Best Stocks to Buy for 2022 According to Analysts

3. United Therapeutics Corporation (NASDAQ:UTHR)

Number of Hedge Fund Holders: 52    

United Therapeutics Corporation (NASDAQ:UTHR) is a biotech firm that develops products for unmet medical needs. The stock has earned positive coverage from analysts recently given a key drug approval by regulatory bodies and a positive review of the Tyvaso DPI product. 

In August, United Therapeutics Corporation (NASDAQ:UTHR) had signed a commercial supply agreement for inhalation profiling devices with MannKind Corporation, a biopharma firm. The agreement lasts until 2026. 

At the end of the third quarter of 2021, 52 hedge funds in the database of Insider Monkey held stakes worth $2.1 billion in United Therapeutics Corporation (NASDAQ:UTHR), up from 45 the preceding quarter worth $2.3 billion.